Skip to main content

Protein kinases in cancer research

Our group is interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation.  We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 in cancer proliferation and survival. We are also interested in the modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer, to improve chemotherapy and immunotherapy treatments.

We are involved in potentiating translational aspects of our resources. We actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it is Clinical Trial Phase II to treat cancer patients with advanced endometrial and squamous NSCLC cancers (NCT02201823). We uncovered the mechanism involved in the antitumor action of ABTL0812: by modulating the Akt/mTORC1 axis and ER stress, this molecule induces cancer cell death by activating cytotoxic autophagy in cancer cells.

Team

Jose Miguel Lizcano De Vega

Jose Miguel Lizcano De Vega

Head of group
Protein kinases in cancer research
Read more
Elisabet Megías Roda

Elisabet Megías Roda

Administration and Management
Protein kinases in cancer research
Read more
Gokhan Gorgisen

Gokhan Gorgisen

Postdoctoral researcher
Protein kinases in cancer research
Read more
Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Predoctoral researcher
Protein kinases in cancer research
Read more
Laura Fresno Bermejo

Laura Fresno Bermejo

Senior researcher
Protein kinases in cancer research
Read more
Nora Diéguez Martínez

Nora Diéguez Martínez

Research technician
Protein kinases in cancer research
Read more
Jose Miguel Lizcano De Vega

Jose Miguel Lizcano De Vega

Head of group
Protein kinases in cancer research
Read more
Elisabet Megías Roda

Elisabet Megías Roda

Administration and Management
Protein kinases in cancer research
Read more
Gokhan Gorgisen

Gokhan Gorgisen

Postdoctoral researcher
Protein kinases in cancer research
Read more
Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Predoctoral researcher
Protein kinases in cancer research
Read more
Laura Fresno Bermejo

Laura Fresno Bermejo

Senior researcher
Protein kinases in cancer research
Read more
Nora Diéguez Martínez

Nora Diéguez Martínez

Research technician
Protein kinases in cancer research
Read more

Projects

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 31/05/2023

Ministerio de Ciencia

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 31/05/2023

Ministerio de Ciencia

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 31/05/2023

Ministerio de Ciencia

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Publications

Methuosis Contributes to Jaspine-B-Induced Cell Death.

PMID: 35806262
Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Year: 2022
Reference: Int J Mol Sci. 2022 Jun 29;23(13). pii: ijms23137257. doi: 10.3390/ijms23137257.
Impact factor: 5.924
Publication type: Paper in international publication
Authors: Bielsa, Nuria; Casasampere, Mireia; Abad, Jose Luis; Enrich, Carlos; Delgado, Antonio; Fabrias, Gemma; Lizcano, Jose M; Casas, Josefina et al.
DOI: 10.3390/ijms23137257

An ERK5-KLF2 signalling module regulates early embryonic gene expression and telomere rejuvenation in stem cells.

PMID: 34780645
Journal: BIOCHEMICAL JOURNAL
Year: 2021
Reference: Biochem J. 2021 Dec 10;478(23):4119-4136. doi: 10.1042/BCJ20210646.
Impact factor: 3.857
Publication type: Paper in international publication
Authors: Gourlay, Robert, Brown, Helen A, Williams, Charles A C, Zhou, Houjiang, Rios-Szwed, Diana, Fernandez-Alonso, Rosalia, Mansoor, Saria, McMulkin, Liam, Toth, Rachel, Peltier, Julien et al.
DOI: 10.1042/BCJ20210646

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.

PMID: 33588149
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Mar;146:87-94. doi: 10.1016/j.ejca.2020.12.019. Epub 2021 Feb 12.
Impact factor: 9.162
Publication type: Paper in international publication
Authors: Gascon, Pere, Domenech, Carles, Vidal, Laura, Victoria, Ivan, Gaba, Lydia, Brunet, Merce, Colom, Helena, Cortal, Marc, Gomez-Ferreria, Mariana, Yeste-Velasco, Marc et al.
DOI: 10.1016/j.ejca.2020.12.019

GRP78 Overexpression Triggers PINK1-IP3R-Mediated Neuroprotective Mitophagy.

PMID: 34440243
Journal: Biomedicines
Year: 2021
Reference: Biomedicines. 2021 Aug 18;9(8). pii: biomedicines9081039. doi: 10.3390/biomedicines9081039.
Impact factor: 6.081
Publication type: Paper in international publication
Authors: Romeo-Guitart, David, Herrando-Grabulosa, Mireia, Munoz-Guardiola, Pau, Polo, Miriam, Banuls, Celia, Petegnief, Valerie, Bosch, Assumpcio, Lizcano, Jose Miguel, Apostolova, Nadezda, Fores, Joaquim et al.
DOI: 10.3390/biomedicines9081039

ERK5 Inhibition Induces Autophagy-Mediated Cancer Cell Death by Activating ER Stress.

PMID: 34805151
Journal: Frontiers in Cell and Developmental Biology
Year: 2021
Reference: Front Cell Dev Biol. 2021 Nov 4;9:742049. doi: 10.3389/fcell.2021.742049. eCollection 2021.
Impact factor: 6.684
Publication type: Paper in international publication
Authors: Gamez-Garcia, Andres, Bolinaga-Ayala, Idoia, Yoldi, Guillermo, Espinosa-Gil, Sergio, Dieguez-Martinez, Nora, Megias-Roda, Elisabet, Munoz-Guardiola, Pau, Lizcano, Jose M et al.
DOI: 10.3389/fcell.2021.742049

The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.

PMID: 32943619
Journal: Cell Death & Disease
Year: 2020
Reference: Cell Death Dis. 2020 Sep 17;11(9):773. doi: 10.1038/s41419-020-02986-w.
Impact factor: 6.304
Publication type: Paper in international publication
Authors: Soriano, Aroa, Jimenez, Carlos, Erazo, Tatiana, Munoz-Guardiola, Pau, Masanas, Marc, Antonelli, Roberta, Boloix, Ariadna, Alfon, Jose, Perez-Montoyo, Hector, Yeste-Velasco, Marc et al.
DOI: 10.1038/s41419-020-02986-w

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.

PMID: 32647375
Journal: Communications Biology
Year: 2020
Reference: Commun Biol. 2020 Jul 9;3(1):366. doi: 10.1038/s42003-020-1092-0.
Impact factor: 4.165
Publication type: Paper in international publication
Authors: Granado-Martinez, Paula, Garcia-Ortega, Sara, Gonzalez-Sanchez, Elena, McGrail, Kimberley, Selgas, Rafael, Grueso, Judit, Gil, Rosa, Naldaiz-Gastesi, Neia, Rhodes, Ana C, Hernandez-Losa, Javier et al.
DOI: 10.1038/s42003-020-1092-0

Blog

News

The meeting allows establishing the basis for collaboration between experts from around the world, with the aim of promoting research on this protein and its role in cancer.

Vall d’Hebron and UAB researchers studied the antitumoral action of protein kinase ERK5 inhibitor drugs, and found out they accelerate toxic autophagy.